Boobis AR, Doe JE, Heinrich-Hirsch B, Meek ME, Munn S, Ruchirawat M, Schlater J, Seed J 2008. IPCS Framework for Analyzing the Relevance of a Noncancer Mode of Action for Humans, Critical Reviews in Toxicology 38:87-96.
Boobis AR, Cohen SM, Dellarco V, McGregor D, Meek ME, Vickers C, Willcocks D, and Farland W (2006). IPCS framework for analyzing the relevance of a cancer mode of action for humans. Critical Reviews in Toxicology 36:781-792.
[This entire issue of Critical Reviews in Toxicology addresses the IPCS framework.]
Cohen SM, Meek ME, Klaunig JE, Patton DE, and Fenner-Crisp PA (2003). The human relevance of information on carcinogenic modes of action: Overview. Critical Reviews in Toxicology, 33:581-589.
Harmonization Project Document No. 2. Chemical-specific adjustment factors for interspecies differences and human variability: guidance document for use of data in dose/concentration–response assessment.
Harmonization Project Document No. 4 Part 1: IPCS framework for analysing the relevance of a cancer mode of action for humans and case-studies Part 2: IPCS framework for analysing the relevance of a non-cancer mode of action for humans.
Meek B., Renwick, A., Ohanian, E. and Sonich-Mullin, C. (2002) Guidance for derivation of chemical-specific adjustment factors (CSAF). Development and implementation, Human Ecol. Risk Assess, 8: 769.
Meek ME, Bucher JR, Cohen SM, Dellarco V, Hill RN, Lehman-McKeeman LD, Longfellow DG, Pastoor T, Seed J, and Patton DE (2003). A framework for human relevance analysis of information on carcinogenic modes of action. Critical Reviews in Toxicology, 33:591-653.
[This entire issue of Critical Reviews in Toxicology (Vol. 33, Issue 6, pp. 581-780) comprises the report of the ILSI Risk Science Institute Working Group on the human relevance of cancer modes of action in animals.]
Meek, B. and Renwick, A. (2006). Guidance for the development of chemical specific adjustment factors - Integration with mode of action frameworks. Toxicokinetics and Risk Assessment, Ed. Lipscomb, J.C. and Ohanian,E.V., Informa Healthcare, New York, N.Y.
Seed J, Carney EW, Corley RA, Crofton KM, DeSesso JM, Foster PMD, Kavlock R, Kimmel G, Klaunig J, Meek ME, Preston RJ, Slikker (Jr) W, Tabacova S, Williams GM, Wiltse J, Zoeller RT, Fenner-Crisp PA, and Patton DE (2005). Overview: Using mode of action and life stage information to evaluate the human relevance of animal toxicity data. Critical Reviews in Toxicology, 35:663-672.
[This entire issue of Critical Reviews in Toxicology (Vol. 35, Issues 8-9, pp. 663-781) comprises the report of an ILSI Risk Science Institute Working Group extending the 2003 human relevance framework to genotoxic carcinogens and non-cancer endpoints.]
Sonich-Mullin C, Fielder R, Wiltse J, Baetcke K, Dempsey J, Fenner-Crisp P, Grant D, Hartley M, Knaap A, Kroese D, Mangelsdorf I, Meek ME, Rice JM, and Younes M (2001). IPCS conceptual framework for evaluating a mode of action for chemical carcinogenesis. Regulatory Toxicology and Pharmacology, 34:146-152.
Swenberg JA, Fryar-Tita E, Jeong YC, Boysen G, Starr T, Walker V, Albertini RJ, 2007. Biomarkers in Toxicology and Risk Assessment: Informing Critical Dose–Response Relationships, Chemical Research in Toxicology 21(1), 253-265.